- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01294059
Effects of Milnacipran on Widespread Mechanical and Thermal Hyperalgesia of Fibromyalgia Patients
July 29, 2014 updated by: University of Florida
Fibromyalgia syndrome (FM) shares many symptoms common to chronic neuropathic pain, including the characteristic hyperalgesia of the skin (thermal, mechanical) and muscles (mechanical) found in almost all FM patients.
Milnacipran, a balance norepinephrine-serotonin re-uptake inhibitor, has been found to reduce pain and improve physical function of FM patients.
However, little is known about the pain mechanisms that are affected by this medication.
Therefore, the investigator wants to determine the efficacy of milnacipran in reducing pain as well as mechanical and thermal hyperalgesia of FM patients during a randomized, double-blind, placebo controlled trial.
Because the investigator expects anti-hyperalgesic effects to coincide or precede with effects on clinical FM pain the proposed duration for this trial is 6 weeks.
Study Overview
Study Type
Interventional
Enrollment (Actual)
51
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32610
- Center for Musculoskeletal Pain Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with diagnosis of chronic wide-spread pain for at least 3 months, who fulfill the 1990 ACR Criteria for FM.
- Patients with mean pain ratings ≥ 4.0 VAS units, at Screening and Baseline visits.
- Patients, who are able to comprehend and satisfactorily comply with protocol requirements.
- Patients who have not taken any pain medications except acetaminophen within 3 days prior to the Baseline Visit (these medications if taken prior to the Screening Visit must be discontinued at Screening Visit and the Baseline Visit may be scheduled at least 7 days past the last dose of these medications).
- All women of childbearing potential (WOCBP) must have a negative urine pregnancy test at the Screening Visit. All women of childbearing potential participating in the study must use a medically acceptable form of contraception
Exclusion Criteria:
- FM patients unwilling or unable to discontinue analgesics (except Tylenol) for at least 5 drug half-lives prior to enrollment.
- Patient has previously failed treatment with Milnacipran for FM pain.
- Patients who have been treated with MAO inhibitors within 30 days prior to the Baseline Visit.
- Patients who received ECT within 3 months prior to the Screening Visit.
- Women who are pregnant or nursing, or women of childbearing potential who do not use adequate contraception, or who are judged to be unreliable in their use of contraception.
- Patients who have participated in any clinical trial within one month prior to the Screening Visit.
- Patients who have a medical condition that, in the Investigator's opinion, would expose them to an increased risk of a significant adverse event or interfere with assessments of safety and efficacy during the course of the trial.
- Patients with severe renal insufficiency (Creatinine clearance < 30 ml/min)
- Patient has a BDI score >29
- Patients with any current malignancy, or any clinically significant hematological, endocrine, cardiovascular, renal, hepatic, gastrointestinal or neurological disease (including any form of epilepsy). If there is a history of such disease but the condition has been stable for at least the past year and is judged by the investigator not to interfere with the patient's participation in the study, the patient may be included.
- Patients with systolic blood pressure greater than 180 mm Hg or less than 90 mm Hg or diastolic blood pressure greater than 105 mm Hg or less than 50 mm Hg at the Screening visit. Similarly, tachycardia of >110/min is exclusionary.
- Patients who require concomitant therapy with any prohibited prescription or over-the-counter medication, including aspirin (except 81 mg for heart disease) or antidepressant medications.
- Patients who are unable to speak, read, and understand English or are judged by the investigator to be unable or unlikely to follow the study protocol and complete all scheduled visits.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Sugar pill
One sugar pill twice daily over 6 weeks
|
50 mg BID Oral x 6 Weeks
Other Names:
|
Active Comparator: Milnacipran
Milnacipran 50 mg bid over 6 weeks
|
50 mg BID Oral x 6 Weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mechanical and Heat Hyperalgesia
Time Frame: 2 week intervals
|
2 week intervals
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Clinical Pain
Time Frame: daily
|
daily
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2009
Primary Completion (Actual)
April 1, 2014
Study Completion (Actual)
April 1, 2014
Study Registration Dates
First Submitted
February 9, 2011
First Submitted That Met QC Criteria
February 9, 2011
First Posted (Estimate)
February 11, 2011
Study Record Updates
Last Update Posted (Estimate)
July 31, 2014
Last Update Submitted That Met QC Criteria
July 29, 2014
Last Verified
July 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Musculoskeletal Diseases
- Rheumatic Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Sensation Disorders
- Somatosensory Disorders
- Fibromyalgia
- Myofascial Pain Syndromes
- Hyperalgesia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Serotonin and Noradrenaline Reuptake Inhibitors
- Milnacipran
- Levomilnacipran
Other Study ID Numbers
- SAV-MD-06
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibromyalgia
-
University of AberdeenCompletedFibromyalgia | Fibromyalgia, Primary | Fibromyalgia, SecondaryUnited Kingdom
-
Eli Lilly and CompanyCompletedFibromyalgia, Primary | Fibromyalgia, SecondaryMexico
-
Rasmia ElgoharyNot yet recruiting
-
Spaulding Rehabilitation HospitalNot yet recruiting
-
Cairo UniversityNot yet recruiting
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed
-
University of UtahTerminated
-
State University of New York - Upstate Medical...CompletedFibromyalgia, PrimaryUnited States
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
Tel-Aviv Sourasky Medical CenterCompletedFibromyalgia (FM)Israel
Clinical Trials on Milnacipran
-
Indiana UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed
-
Pierre Fabre MedicamentCompletedFibromyalgia SyndromeSpain, Italy, Portugal, France, Czech Republic, Finland, Germany, Norway, Romania, Sweden, Denmark, Poland, United Kingdom
-
Chang Gung Memorial HospitalUnknownDepression | Ischemic StrokeTaiwan
-
California Medical Clinic for HeadacheUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraUnited States
-
Forest LaboratoriesCompleted
-
Pierre Fabre MedicamentCompletedFibromyalgia SyndromeSpain, Italy, Portugal, France, Czech Republic, Finland, Germany, Norway, Romania, Sweden
-
Valera BussellForest LaboratoriesCompleted
-
Forest LaboratoriesCypress Bioscience, Inc.Completed
-
Dr. Norman HardenForest LaboratoriesCompletedChronic Pain | Knee Osteoarthritis | Degenerative Joint Disease
-
Duke UniversityCompletedOsteoarthritis Pain | Knee Pain After Total Knee ArthroplastyUnited States